Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 50c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of ($0.26), $0.50 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $61.5 million versus the consensus estimate of $48.56 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c